Follow The Filings

HIMS Hims & Hers Health Inc.

Health Care, filed as HIMS & HERS HEALTH INC (COM CL A), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 1 Owner
  • Max 0.1%
  • $5.5M
  • 2 exits

In 2026 Q2 David Witzke and Farallon Capital Management sold out of Hims & Hers Health.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Davidson Kempner Capital Management). Not free-float ownership.

  1. Davidson Kempner Capital Mana... 0.07%

Who owns HIMS

Sorted by value, long equity only, as of 2026 Q2.

History
Davidson Kempner Capital Management 0.07% Hold 160,012 $5.5M History
David Witzke, Avidity Partners Management exited 2026 Q2 Last 2026 Q1 0.31% Exit −0.31% 50,000 $1.4M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 10,000 $208K History

1 current, 2 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by HIMS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HIMS insider trades
  • $1.2M bought by 1 insider
  • $98K sold by 1 insider outside a trading plan
  • $19.3M sold by 7 insiders under 10b5-1 plans
  1. Soleil Boughton Chief Legal Officer
    Planned sale
    $96K 3,462 shares at $27.60 1.2% of stake
    Traded Oct 28 Filed Oct 29
    ↗
  2. Soleil Boughton Chief Legal Officer
    Planned sale
    $101K 3,461 shares at $29.06 1.2% of stake
    Traded Oct 14 Filed Oct 15
    ↗
  3. Oluyemi Okupe CFO
    Planned sale
    $59K 2,000 shares at $29.70 0.8% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  4. Soleil Boughton Chief Legal Officer
    Planned sale
    $101K 3,461 shares at $29.17 1.1% of stake
    Traded Sep 30 Filed Oct 2
    ↗
  5. Oluyemi Okupe CFO
    Planned sale
    $877K 29,277 shares at $29.95 11% of stake
    Traded Sep 22 Filed Sep 23
    ↗
  6. Oluyemi Okupe CFO
    Planned sale
    $355K 12,313 shares at $28.82 4.7% of stake
    Traded Sep 17 Filed Sep 18
    ↗
  7. Mohamed Elshenawy CTO
    Planned sale
    $226K 7,954 shares at $28.39 4.1% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  8. Michael Chi COO
    Planned sale
    $398K 14,027 shares at $28.39 3% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  9. Soleil Boughton Chief Legal Officer
    Planned sale
    $174K 6,236 shares at $27.86 2% of stake
    Traded Sep 16 Filed Sep 17
    ↗
  10. Soleil Boughton Chief Legal Officer
    Planned sale
    $98K 3,458 shares at $28.33 1.1% of stake
    Traded Sep 2 Filed Sep 3
    ↗
  11. Oluyemi Okupe CFO
    Planned sale
    $148K 4,938 shares at $29.99 1.8% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  12. Deborah M. Autor Chief Policy Officer
    Planned sale
    $467K 16,773 shares at $27.85 26% of stake
    Traded Aug 18 Filed Aug 20
    ↗
  13. Soleil Boughton Chief Legal Officer
    Planned sale
    $692K 25,111 shares at $27.55 7.4% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  14. Oluyemi Okupe CFO
    Planned sale
    $2.2M 64,771 shares at $34.05 20% of stake
    Traded Jun 18–Aug 17 Filed Aug 18
    ↗
  15. Oluyemi Okupe CFO
    Planned sale
    $229K 7,163 shares at $31.99 2.5% of stake
    Traded Jul 17 Filed Jul 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 68 option exercises, 33 share withholdings for taxes, 12 gifts, 4 stock grants, and 2 other transactions.

Congress

1 member of Congress traded HIMS in the last three years: 1 buy and 0 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Aug 4, 2025 filed Sep 12, 2025

SEC filings

Recent issuer filings from EDGAR, 5 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13D/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.872B $1.48B $2.35B
Gross profit $0.715B $1.17B $1.73B
Gross margin * 82.0% 79.5% 73.8%
Net income -$23.55M $126.04M $128.36M
Net margin * -2.7% 8.5% 5.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $265.05M $395.83M $767.64M
Total non-current assets * $0.176B $0.312B $1.39B
Total assets $0.441B $0.708B $2.15B
Total current liabilities $88.47M $221.37M $404.43M
Total non-current liabilities * $0.009B $0.009B $1.21B
Total equity $344.03M $476.72M $540.93M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $73.48M $251.08M $300.01M
Cash from investing -$0.012B -$0.019B -$1.02B
Cash from financing -$11.48M -$107.84M $729.62M
Net change in cash $49.89M $123.92M $7.18M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.